TELA Bio (TELA) Q4 2025 earnings review
Record Revenue and Flat OpEx Mask a Severe Guidance Cut
TELA Bio finished 2025 with record Q4 revenue of $20.9M (+18% YoY) and successfully held full-year operating expenses flat, demonstrating strong operational leverage. The company also secured a $70M credit facility from Perceptive Advisors, extending its financial runway. However, the positive Q4 results are entirely eclipsed by a shocking deceleration in forward guidance. Management guided for 'at least 8%' growth in 2026, a massive walk-down from the 'at least 15%' preliminary outlook provided just three months ago. Worse, Q1 2026 revenue guidance of $18.5M implies 0% YoY growth, suggesting a severe stall in momentum despite expanding the sales force to 88 reps.
🐂 Bull Case
The company proved it can scale without ballooning costs. Full-year 2025 revenue grew 16%, while operating expenses remained flat at $88.1M, clearing a major hurdle on the path to profitability.
With $50.8M in cash at year-end and a new $60M initial draw from a $70M Perceptive Advisors credit facility, liquidity concerns are off the table for the foreseeable future.
🐻 Bear Case
The initial Q1 2026 guidance of $18.5M implies exactly 0% YoY growth compared to Q1 2025. This sharply contradicts the narrative of a ramped-up, highly productive sales force driving re-acceleration.
The mix shift toward smaller hernia products (like OviTex IHR) continues to weigh on average selling prices, meaning TELA has to work much harder on volume just to keep revenue flat.
⚖️ Verdict: 🔴
Bearish. While Q4 execution and OpEx control were commendable, a growth company guiding for 0% YoY growth in the upcoming quarter and slashing its annual outlook breaks the core investment thesis. Execution risks appear higher than management is letting on.
Key Themes
The Q3 to Q4 Guidance Reversal
During the Q3 2025 call, management confidently provided an initial 2026 outlook of 'at least 15% growth.' Just three months later, the official 2026 guidance has been slashed to 'at least 8%.' This Decelerating trend indicates either severe disruptions in sales force productivity, intensifying competitive pressure, or much worse ASP headwinds than previously disclosed. The guidance cut directly contradicts the CEO's statement that 'the team we have assembled is the best we have ever had.'
OpEx Discipline and Leverage
Stable. TELA successfully executed its promise to hold 2025 operating expenses flat. Despite hiring new sales reps and investing in commercial reorganization, Q4 OpEx was $20.4M (up only slightly from $19.6M in 24Q4) and full-year OpEx actually dropped slightly to $88.1M. This rigorous cost control significantly reduced the annual operating loss.
ASP Pressures from Mix Shift
Stable. The company continues to report that revenue growth is being partially offset by a shift in the hernia product mix toward smaller-sized units. As minimally invasive and robotic procedures (using products like OviTex IHR and LIQUIFIX FIX8) take a larger share of volume, the lower average selling prices require TELA to drive significantly higher unit volumes to maintain revenue growth.
Sales Force Expansion Reaches Target
Accelerating. After the disruptive exodus of sales reps in late 2024, TELA has successfully rebuilt its commercial team, reaching 88 quota-carrying representatives as of the Q4 release. This provides a broad geographic footprint. The critical unknown is how long it will take this new cohort to reach full productivity, given the weak Q1 2026 guidance.
Clinical Validation in Plastic & Reconstructive Surgery
Stable. TELA continues to lean heavily on clinical data to drive adoption away from synthetic mesh. The OviTex PRS line, specifically the larger-sized configurations launched this year in the US, is a key growth driver, capturing share in the $800M US Plastic & Reconstructive Surgery market. Over 1,500 patients are now featured in peer-reviewed publications.
Macro and Tariff Vulnerabilities
Stable. The company remains exposed to macroeconomic trade policies, specifically previously disclosed tariffs on products imported from New Zealand (which management noted could impact gross margins by 50-100 bps). While Q4 gross margins improved to 65.9%, any escalation in supply chain costs or tariffs will directly threaten the timeline to profitability.
Other KPIs
Accelerating. Improved from 63.6% in the prior year period. Management attributed this improvement to lower expense recognized for excess and obsolete inventory adjustments as a percentage of revenue, indicating better inventory management and a stabilization of the new product transition.
Stable. A slight improvement from a loss of $34.1 million in 2024. Despite a $11.0M increase in revenue, the operating loss barely budged due to higher sales commissions and development costs absorbing the gross profit gains. However, holding the absolute dollar loss flat while scaling top-line is a step in the right direction.
Stable. Cash balance remains healthy, completely separate from the new Perceptive Advisors credit facility which closed after the quarter ended. Combined, the company has access to over $110M in liquidity, removing any near-term financing overhang.
Guidance
Decelerating. Implies roughly $86.7M in revenue. This is a sharp drop from 16% growth in 2025 and 19% in 2024. More importantly, it is a massive walk-back from the 'at least 15%' preliminary 2026 outlook management discussed during the Q3 2025 call.
Decelerating. Q1 2025 revenue was exactly $18.5M. This guidance implies essentially 0% year-over-year growth for the first quarter. Furthermore, it represents an 11% sequential decline from Q4 2025 ($20.9M), which is a larger seasonal drop than the company has historically experienced.
Key Questions
Guidance Reversal
During the Q3 call, you provided a preliminary 2026 growth outlook of 'at least 15%.' Now, you are guiding for 'at least 8%.' What specifically deteriorated in the business over the last 90 days to warrant cutting the growth outlook nearly in half?
Q1 Stagnation
Guidance of $18.5M for Q1 implies 0% year-over-year growth. With 88 quota-carrying reps now in the field, why is the top line stalling completely in the first quarter?
Sales Rep Productivity Ramp
You noted that the team of 88 reps is 'the best we have ever had.' What is the expected time to productivity for the newer cohorts, and how much of the 2026 guidance relies on reps who have been with the company for less than six months?
Pricing vs Volume
You cited a shift toward smaller-sized hernia units weighing on ASPs. Can you quantify the ASP headwind experienced in Q4, and is the flat Q1 revenue guidance primarily a function of this pricing pressure or a slowdown in actual unit volumes?